Capricor Therapeutics Inc., of Los Angeles, reported preclinical data for multiple treatments of its cellular therapy, CAP-1002, at the 11th Annual Neuromuscular Translational Research Conference in Cambridge, U.K. In the mdx mouse model of Duchenne muscular dystrophy, multiple administrations were possible due to the low immunogenic profile and immunomodulatory capabilities of the drug.